MedTrace Logo

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

NCT04826562 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-10-11

No results posted yet for this study

Summary

An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy who are virological suppressed (HIV-1 \< 50 copies/mL

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

Dolutegravir/Lamivudine

single tablet antiretroviral

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Saint Michael's Medical Center

    lead OTHER

Principal Investigators

  • Jihad Slim, MD · Saint Michael's Medical Cettner

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-26
Primary Completion
2023-10-06
Completion
2023-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04826562 on ClinicalTrials.gov